Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


At Liraglutide Panel Review, A Call For CV Studies To Look Beyond MACE

Executive Summary

If cardiovascular studies are required for non-cardiac drugs, they should be focused on specific signals of heart-related concern that may not include ischemic events, advisory committee cardiologists say during review of Novo Nordisk’s Saxenda for obesity.

You may also be interested in...

Diabetes CV Endpoints Suffer Renewed Criticism At Empagliflozin Meeting

EMPA-REG data for Boehringer/Lilly's Jardiance highlight need to rethink diabetes trials' current three-point MACE endpoint that is heavily focused on atherosclerosis, FDA advisors say.

Empagliflozin's CV Benefit Impresses At EASD, But What Will FDA Say?

Boehringer/Lilly's Jardiance delivers impressive CV death benefit but no effect on myocardial infarction or stroke – prompting questions about relevance of MACE composite primary endpoint.

Diabetes CV Trials May Look Different From SAVOR, EXAMINE In Future

Outcomes trials of AstraZeneca’s saxagliptin and Takeda’s alogliptin provide reassurance on cardiovascular risks but raise other safety concerns that are difficult to interpret due to the studies’ high-risk populations and ischemia-focused endpoints.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts